Our Science
Pipeline & Products
- Products
- Clinical Trials
Resources
- Education
- Press Releases
Who We Are
- Our Team
- Partnership
Careers
- Corporate Culture
Contact Us

/ November 15, 2024

Dan Dunham, Esq

Related

Press Release / July 30, 2026

NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.

Press Release / June 26, 2026

Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

Press Release / June 23, 2026

NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital

Our Science
Pipeline & Products
Who We Are
News
Careers
Contact Us

View our Privacy Notice, Terms of Use and Corporate Compliance.

Consumer Health Data Privacy Notice

© 2026 NS Pharma, Inc. All rights reserved.
NS Pharma, the NS Pharma symbol and Viltepso are registered trademarks of Nippon Shinyaku Co., Ltd. We Speak Duchenne, We Speak Duchenne logo and the NS Support logo are registered trademarks of NS Pharma, Inc.

US-NSPCO-0107